Elosulfase alfa 5mg/5ml solution for infusion vials
NHS hospitals in England used £26,782,500 of indicative cost of Elosulfase alfa 5mg/5ml solution for infusion vials in the 12 months to April 2026, about 0.1% of all hospital medicines spend. That is up 13.2% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Elosulfase alfa 5mg/5ml solution for infusion vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Elosulfase alfa 5mg/5ml solution for infusion vials most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Salford Royal Nhs Foundation Trust | £8,875,500 |
| University College London Foundation Tr | £5,769,000 |
| Manchester University Nhs Ft | £5,396,250 |
| Royal Free London Nhs Foundation Trust | £1,629,000 |
| Univ Hpls Bristol Nhs Foundation Trust | £54,000 |
| Birmingham Womans & Childrens Nhs Ft | £7,500 |
The primary-care picture
Elosulfase alfa is also dispensed in the community. See the national primary-care prescribing volume, cost and trend on the Elosulfase alfa medicine page.